Alterations of Glucose Metabolism in HIV-Infected Patients
- 37 Downloads
Purpose of Review
The life expectancy of patients living with human immunodeficiency virus (HIV) has dramatically improved with newer antiretroviral therapy (ART), but these agents are associated with significant increase in metabolic and other non-communicable diseases. The potential for alteration in glucose metabolism should be kept in mind to optimize diagnosis and treatment. The purpose of this review is to assess the pathophysiologic mechanisms by which patients living with HIV may have their glucose metabolism altered and mention the available evidence to improve prompt screening, diagnosis, and treatment.
HIV can impair glucose metabolism primarily by inflammation pathways, but most metabolic alteration is related to antiretroviral agents, usually protease inhibitors (PIs). Although glucose management is similar to the general population, newer agents are being investigated to improve glucose metabolism specifically in HIV-infected patients.
HIV-infected patients should be considered at high risk for alterations of glucose metabolism, including insulin resistance, pre-diabetes, and diabetes, especially after initiating ART. Patients should have glucose screening every 6 to 12 months and every 3 months after initiating ART. Treatment remains similar to the general population, but interactions with antiretroviral agents should be kept in mind.
KeywordsGlucose metabolism Diabetes mellitus HIV
Compliance with Ethical Standards
Conflict of Interest
The author declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 1.Crum N, Riffenburgh R, Wegner S, Agan B, Tasker S, Spooner K, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41(2):194–200.CrossRefPubMedGoogle Scholar
- 5.Gutierrez A, Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine 2012;41:1–10.Google Scholar
- 10.• Fortuny C, Deya-Martínez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J. 2015;34:36–43. This article summarizes the metabolic complications that can be observed in children and adolescents infected with HIV and provides general management guidelines. CrossRefGoogle Scholar
- 11.•• Willig A, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289–96. This article provides information and management guidelines for complications that can occur in adults infected with HIV. CrossRefPubMedPubMedCentralGoogle Scholar
- 20.d’Etorre G, Ceccarelli G, Zaccarelli M, Ascoli-Bartoli T, Bianchi L, Bellelli V, et al. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: ATAzanavir & GLUcose metabolism (ATAGLU) study. Int J STD AIDS. 2015:1–6.Google Scholar
- 23.Menezes CN, Crowther NJ, Duarte R, Van Amsterdam D, Evans D, Dickens C. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014;15:3–12.CrossRefPubMedGoogle Scholar
- 28.• American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;40(1):1–142. These guidelines are important since most HIV-infected adults with diabetes should be managed in a similar way to the general population. The recommendations mentioned here apply to most HIV-infected patients with diabetes. Google Scholar
- 30.Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11(158)Google Scholar
- 39.Schambelan M, Benson CA, Carr A, Currier JS, Dubé M, Gerber JG, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS Society–USA panel. J Acquir Immune Defic Syndr. 2002;31:257–75.CrossRefPubMedGoogle Scholar
- 46.Rao MN, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg M, et al. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab. 2010;95:4361–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605–11.CrossRefPubMedGoogle Scholar
- 51.Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009;94:1137–44.CrossRefPubMedPubMedCentralGoogle Scholar